Transient increase in circulating basophils and eosinophils in dupilumab-associated conjunctivitis in patients with atopic dermatitis
M Katsuta, Y Ishiuji, H Matsuzaki… - Acta Dermato …, 2021 - pmc.ncbi.nlm.nih.gov
M Katsuta, Y Ishiuji, H Matsuzaki, K Yasuda, B Kharma, Y Nobeyama, T Hayashi, Y Tokura…
Acta Dermato-Venereologica, 2021•pmc.ncbi.nlm.nih.govMATERIALS AND METHODS To delineate the clinical parameters associated with the
occurrence of DAC, this study retrospectively investigated the clinical course of 28 patients
with AD who were treated with dupilumab and completed a 6-months period of treatment
between August 2018 and May 2019. The study was approved by Institutional Review Board
(IRB) of The Jikei University School of Medicine. All patients were treated with dupilumab
(300 mg every other week). DAC was defined as the presence of conjunctival hyperaemia …
occurrence of DAC, this study retrospectively investigated the clinical course of 28 patients
with AD who were treated with dupilumab and completed a 6-months period of treatment
between August 2018 and May 2019. The study was approved by Institutional Review Board
(IRB) of The Jikei University School of Medicine. All patients were treated with dupilumab
(300 mg every other week). DAC was defined as the presence of conjunctival hyperaemia …
MATERIALS AND METHODS
To delineate the clinical parameters associated with the occurrence of DAC, this study retrospectively investigated the clinical course of 28 patients with AD who were treated with dupilumab and completed a 6-months period of treatment between August 2018 and May 2019. The study was approved by Institutional Review Board (IRB) of The Jikei University School of Medicine. All patients were treated with dupilumab (300 mg every other week). DAC was defined as the presence of conjunctival hyperaemia, tearing and pruritus (3, 4). Notably, the patients were strictly monitored for ocular manifestations every 2 weeks over a period of 6 months, with no missing data.
pmc.ncbi.nlm.nih.gov
